CN111278853A - 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化 - Google Patents

基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化 Download PDF

Info

Publication number
CN111278853A
CN111278853A CN201880069666.9A CN201880069666A CN111278853A CN 111278853 A CN111278853 A CN 111278853A CN 201880069666 A CN201880069666 A CN 201880069666A CN 111278853 A CN111278853 A CN 111278853A
Authority
CN
China
Prior art keywords
ser
seq
gly
peg
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880069666.9A
Other languages
English (en)
Other versions
CN111278853B (zh
Inventor
王蕾
欧阳建梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Turier Biotech Co ltd
Original Assignee
Shenzhen Turier Biotech Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Turier Biotech Co ltd filed Critical Shenzhen Turier Biotech Co ltd
Priority to CN202210478829.7A priority Critical patent/CN114920818B/zh
Publication of CN111278853A publication Critical patent/CN111278853A/zh
Application granted granted Critical
Publication of CN111278853B publication Critical patent/CN111278853B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明涉及一类具有胰高血糖素样肽‑1受体(Glucagon‑like peptide‑1receptor，GLP‑1R)和胰高血糖素受体(Glucagon receptor，GCGR)双激动效应的多肽化合物的用途，其具有高酶解稳定性、高生物活性、无不良反应等特点，能够明显改善BDL诱导的大鼠胆汁淤积性肝纤维化程度,对胆汁性肝硬化等疾病具有显著的治疗作用。该类双靶点激动剂多肽可用于预防或治疗胆汁性肝硬化及相关肝纤维化疾病。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880069666.9A 2017-11-06 2018-10-19 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化 Active CN111278853B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210478829.7A CN114920818B (zh) 2017-11-06 2018-10-19 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017110792725 2017-11-06
CN201711079272 2017-11-06
PCT/CN2018/111030 WO2019085772A1 (zh) 2017-11-06 2018-10-19 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210478829.7A Division CN114920818B (zh) 2017-11-06 2018-10-19 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化

Publications (2)

Publication Number Publication Date
CN111278853A true CN111278853A (zh) 2020-06-12
CN111278853B CN111278853B (zh) 2022-06-21

Family

ID=66332826

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201880069666.9A Active CN111278853B (zh) 2017-11-06 2018-10-19 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
CN202210478829.7A Active CN114920818B (zh) 2017-11-06 2018-10-19 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
CN201811265403.3A Withdrawn CN109745547A (zh) 2017-11-06 2018-10-29 Glp-1r/gcgr双激动剂多肽治疗胆汁性肝硬化
CN201811265255.5A Withdrawn CN109745549A (zh) 2017-11-06 2018-10-29 Glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202210478829.7A Active CN114920818B (zh) 2017-11-06 2018-10-19 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
CN201811265403.3A Withdrawn CN109745547A (zh) 2017-11-06 2018-10-29 Glp-1r/gcgr双激动剂多肽治疗胆汁性肝硬化
CN201811265255.5A Withdrawn CN109745549A (zh) 2017-11-06 2018-10-29 Glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化

Country Status (4)

Country Link
US (1) US11419918B2 (zh)
EP (1) EP3708577B1 (zh)
CN (4) CN111278853B (zh)
WO (1) WO2019085772A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112472794A (zh) * 2020-11-17 2021-03-12 深圳市图微安创科技开发有限公司 双靶点激动剂多肽治疗anit介导的pbc及其相关的肝纤维化
CN112625093A (zh) * 2020-12-29 2021-04-09 清远市图微安创科技开发有限公司 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物
CN112791178A (zh) * 2021-01-22 2021-05-14 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双激动剂多肽衍生物预防或治疗肾纤维化
CN112791178B (zh) * 2021-01-22 2024-10-29 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双激动剂多肽衍生物预防或治疗肾纤维化

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111423506B (zh) * 2019-11-08 2023-06-27 成都奥达生物科技有限公司 一种glp-1化合物
CN111944062B (zh) * 2019-12-09 2023-11-07 深圳市体内生物医药科技有限公司 一种识别Fc片段的嵌合抗原受体及其应用
CN113292646B (zh) * 2020-05-29 2022-05-13 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
CN114349828B (zh) * 2020-11-27 2023-12-08 江苏师范大学 Glp-1/胰高血糖素受体双重激动剂及其应用
CN112891512B (zh) * 2021-01-22 2024-07-26 清远市图微安创科技开发有限公司 多肽化合物在预防或治疗肝纤维化中的应用
KR20240103040A (ko) * 2021-11-19 2024-07-03 소테르 바이오파마 피티이. 리미티드 스테이플-함유 폴리펩티드 및 이의 적용
CN114790236A (zh) * 2022-03-09 2022-07-26 深圳市图微安创科技开发有限公司 一种gcgr/glp-1r双靶点激动多肽的合成方法
WO2023231730A2 (zh) * 2022-06-01 2023-12-07 信达生物制药(苏州)有限公司 使用mazdutide的治疗方法
CN115536739B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071393A2 (en) * 2003-02-13 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r)
WO2006005469A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
CN106046145A (zh) * 2016-04-22 2016-10-26 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化
CN106519015A (zh) * 2014-09-23 2017-03-22 蒋先兴 胃泌酸调节素类似物
CN107106660A (zh) * 2014-09-16 2017-08-29 韩美药品株式会社 长效glp‑1/胰高血糖素受体双激动剂对于治疗非酒精性脂肪肝疾病的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181887A1 (en) * 2005-09-08 2009-07-16 Gastrotech Pharma A/S Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
TWI674270B (zh) * 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
EP3209682B1 (en) * 2014-10-24 2020-12-30 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
EA201892625A1 (ru) * 2015-01-09 2019-07-31 Джилид Аполло, Ллс КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
JP2018511329A (ja) * 2015-04-01 2018-04-26 ザ スクリプス リサーチ インスティテュート Ｇｐｃｒアゴニストポリペプチドに関連する方法および組成物
TWI783244B (zh) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
JP6960120B2 (ja) * 2015-12-22 2021-11-05 ロート製薬株式会社 肝疾患治療剤及び肝疾患を治療する方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071393A2 (en) * 2003-02-13 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r)
WO2006005469A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
CN107106660A (zh) * 2014-09-16 2017-08-29 韩美药品株式会社 长效glp‑1/胰高血糖素受体双激动剂对于治疗非酒精性脂肪肝疾病的应用
CN106519015A (zh) * 2014-09-23 2017-03-22 蒋先兴 胃泌酸调节素类似物
CN106046145A (zh) * 2016-04-22 2016-10-26 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
XING-CHUN WANG，等: "Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation", 《WORLD JOURNAL OF GASTROENTEROLOGY》 *
任星峰，等: "纤维化淤胆性肝炎肝组织α-SMA及Ⅰ、Ⅲ型胶原的表达", 《中国医师进修杂志》 *
温伟波: "《中医肝胆学》", 31 August 2016, 昆明：云南大学出版社 *
王嘉森，等: "胆汁性肝硬化中胆管细胞增生的调节因子", 《肝脏》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112472794A (zh) * 2020-11-17 2021-03-12 深圳市图微安创科技开发有限公司 双靶点激动剂多肽治疗anit介导的pbc及其相关的肝纤维化
CN112625093A (zh) * 2020-12-29 2021-04-09 清远市图微安创科技开发有限公司 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物
CN112791178A (zh) * 2021-01-22 2021-05-14 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双激动剂多肽衍生物预防或治疗肾纤维化
CN112791178B (zh) * 2021-01-22 2024-10-29 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双激动剂多肽衍生物预防或治疗肾纤维化

Also Published As

Publication number Publication date
EP3708577A4 (en) 2021-09-01
CN109745547A (zh) 2019-05-14
US20210187074A1 (en) 2021-06-24
US11419918B2 (en) 2022-08-23
CN114920818A (zh) 2022-08-19
WO2019085772A1 (zh) 2019-05-09
EP3708577B1 (en) 2024-09-04
CN109745549A (zh) 2019-05-14
EP3708577A1 (en) 2020-09-16
CN111278853B (zh) 2022-06-21
CN114920818B (zh) 2024-02-27

Similar Documents

Publication Publication Date Title
CN111278853B (zh) 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
CN106046145B (zh) Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化
JP6895883B2 (ja) オキシントモジュリン類似体、薬物組成物、糖尿病治療薬、血糖降下薬及び体重低下薬
AU2024203093A1 (en) Polypeptide compounds and use thereof in the prevention or treatment of diabetes or diagnostic compounds
CN111372945B (zh) 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗特发性肺间质纤维化
CN114585640B (zh) Glp-1r/gcgr双靶点激动剂多肽衍生物治疗病毒性肝炎相关的肝纤维化
EP4289860A1 (en) Use of polypeptide compound in prevention or treatment of inflammatory bowel disease and intestinal fibrosis related thereto
CN112472794A (zh) 双靶点激动剂多肽治疗anit介导的pbc及其相关的肝纤维化
CN112791178A (zh) Glp-1r/gcgr双激动剂多肽衍生物预防或治疗肾纤维化

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant